We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Bioquell | BQE | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 597.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 597.00 |
| Top Posts |
|---|
Posted at 24/1/2019 12:53 by dab26 Not yet.Interactive Investors indicate January 30th. Hope that is of some help. |
Posted at 15/9/2018 08:30 by countless The Motley Fool had an article on BQE yesterday folks. You should be able to find it via Google but in short it states 'having positioned itself for more predictable revenues and higher quality earnings, it now expects to exceed analyst predictions on full-year profit. The only downside to this is that the shares look even more expensive than before (tipped at 342p with a gain of 60%). At 45 times forecast earnings before today, investors will need to be very confident that BQE will keep its word. While I would not necessarily dispose of the stock just yet, it does pay to remember that high expectations frequently result in eventual disappointment'.If I was a holder and noting that momentum is falling I would bank some profits or at the very least protect them. Have to say I like the TMF website for info. Always balanced. BH i have a few interesting links for your new BB will post when not on laptop (not sure how to cut and paste without a mouse!) |
Posted at 02/9/2018 22:38 by countless I have sent you a PM bountyhunter because I was not sure if Money Week would be happy with me summarising their article to the whole world!Interesting article from Investors Chronicle - strange how share tipsters regurgitate stuff. I noticed Frontier Tech Investor increased their up to purchase price to £5.50 last week because of the momentum. My view is that a market cap of £128m cannot be supported with an expected profit of £3.5m - that's a whopping 36.5x especially because I think BQE will struggle to significantly increase their turnover. Their HPV product will not take off in the NHS even though it may be the gold standard. What they have sold to the NHS to date is pitiful - mainly because the NHS is bust.Why buy an expensive machine that pumps out bleach when good old elbow grease will do. Their other products are very specialised to the extent I do not think it can significantly increase turnover in the short/medium term. Five years away when cancer research is at a different stage then perhaps unless the competition moves in. The share price has raced too far ahead of itself. Best of luck to all though. I was wrong with my small short but think my logic here is sound. |
Posted at 19/8/2018 14:27 by countless It was tipped recently by Eoin Treacy of Frontier Tech Investor. I think he has to produce a tip a month for his followers. Energy / healthcare / tech advances are his thing. As with most tipsters hit and miss. Hope this helps. |
Posted at 03/1/2018 13:52 by interceptor2 Investors positioning ahead of next update? |
Posted at 19/3/2017 20:18 by pavey ark bh, I suppose you've discovered this by now but the rise was very probably due to the recent positive update in Investors Chronicle.I sold on Friday simply because I expect the price to drift back and a 15% gain in a couple of months was more than OK. I've been wrong before but the gain is fine even if the price doesn't come back down. If the price falls I'll almost certainly buy back in as I like the company. |
Posted at 22/6/2016 11:04 by cockerhoop To clarify individual brokers will only get 50% of the total holding of it's customers but say a broker has 10 nominee investors with equal holdings in BQE, 9 opt to tender 100% and the 10th is away holiday or forgot to tender. Because the brokers 50% allocation is covered by the 9 wanting 100% the 10th's allocation is shared amongst the 9. |
Posted at 05/5/2016 09:16 by cockerhoop Pavey Ark,Your comments regards investors awaiting ST's thoughts appear spot on :-) |
Posted at 29/4/2016 10:45 by cockerhoop Galles,It normally works that investors will be invited to tender at £2 per share. The investor will then through their broker specify the % of their holding they wish to tender 0-100%. if everyone tendered 100% then 50% of all investors holdings would be purchased and cancelled. Often though not everyone tenders. PaveyArk for example may see £2 as undervaluing his holding and not tender, waiting for the possible £2.20 paid once the rump of the company is sold. These shares would then be offered to other investors so it's quite possible that greater than 50% tender occurs for individual investors. It's always worth looking at what the execs do with their holdings in the tender as I imagine they have a pretty good idea of the value of the remaining business or likely return. |
Posted at 04/4/2016 20:42 by pavey ark I've just had a look as far back as 2009 and the results are always in the 18th/22nd March slot so it looks like something different is happening this year.If the review had come to nothing I would expect an announcement with the results and the results to be in the usual date slot. I am willing to bet that some development has taken place but the big question is whither it is an outright sale or a merger. A merger with a larger company should result in cash return to existing BQE shareholders but not the takeout bonus that most expect. A sale would,in my opinion,result in a premium (substantial ?)to the current share price as I always felt that ST in the Investors Chronicle was undervaluing the remaining business but only time will tell and I suspect that time is close. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
